BCL2 R107_R110dup

CI-VAR-00003616Explore in graph →CIViC 3029

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Lymphocytic Leukemia1
BCL2 R107_R110dup	Venetoclax	Predictive	B	Supports Resistance	4	submitted	EID8309 This study is a follow-up report after the original publication (PMID 30514704). R107_R110dup mutation was identified in combination with other BCL2 mutations including G101V in 5 CLL patients with ve… (full text at CIViC) PMID 31951646 · Blombery et al., 2020 · Open in CIViC	civic
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1
BCL2 R107_R110dup	Venetoclax	Predictive	B	Supports Resistance	3	submitted	EID8188 Associated with venetoclax resistance in high-risk CLL patients post ibrutinib in 2 cases of "progressive CLL" and 1 case of Richter transformation PMID 32232486 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.